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Available online 16 April 2016Introduction: In addition to its central role in coagulation, thrombin is involved in non-hemostatic activities such
as inﬂammation. Direct inhibition of thrombin activity (e.g. with dabigatran) or reducing its generation by inhi-
bition of Factor Xa (e.g. with rivaroxaban) may therefore have anti-inﬂammatory effects.
Materials and Methods: Microarray experiments were performed to identify transcriptome-wide changes in
mRNA expression levels induced by thrombin in the presence and absence of the PAR-1 antagonist vorapaxar
in primary human umbilical vein endothelial cells (HUVECs). On this basis, HUVECs were incubated with
recalciﬁed plasma, with or without rivaroxaban (0.3–3000 nM), dabigatran (0.3–10,000 nM), or vorapaxar
(0.3–10 nM). Expression levels of preselected pro-inﬂammatory genes were quantiﬁed by real-time PCR.
Results: Vorapaxar abolished 67 of the 69 transcripts altered by more than twofold on addition of thrombin to
HUVECs. ELAM-1, VCAM-1, ICAM-1, MCP-1, IL-8, CXCL1, and CXCL2 were among the genes most strongly
induced by thrombin. Inﬂammatory gene expression after stimulation of thrombin generation was
concentration-dependently suppressed by vorapaxar, dabigatran, and rivaroxaban. However, dabigatran at low
concentrations (3–300 nM) increased signiﬁcantly the expression levels of CXCL1, CXCL2, IL-8, ELAM-1, MCP-
1, and tissue factor.
Conclusion: In HUVECs, plasma-induced transcriptional changes are mediated by thrombin-induced PAR-1
activation. Rivaroxaban downregulated the expression of pro-inﬂammatorymarkers and tissue factor to a similar
extent to dabigatran.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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. This is an open access article under(e.g. chemokines and interleukins), leukocyte adhesion molecules, tis-
sue factor (TF), and coagulation proteases (e.g. Factor Xa, thrombin)
are major contributors [1–3]. Proteinase-activated receptors (PARs)
form the molecular connection between coagulation and inﬂammation
[1,2]. Four PARs (PAR-1–4) have been identiﬁed and have been found to
be expressed on the membranes of several cell types, including endo-
thelial cells, leukocytes, and platelets. PAR-1, ‐3, and ‐4, are thrombin
receptors that are activated rapidly by thrombin, whereas Factor Xa
activates PAR-1 and ‐2 [1,4].
Thrombin is a multifunctional molecule and its non-hemostatic
activities have been well documented [4,5]. In addition to its central
role in coagulation and thrombus formation, thrombin elicits multiple
effects on a variety of cell types, including endothelial cells. Tomodulate
endothelial functions, thrombin alters the expression of genes related to
hemostasis, cell adhesion, and inﬂammation. In the vascular endotheli-
um, thrombin is able to mobilize adhesive molecules to the endothelial
surface and to stimulate cytokine production [4]. PAR-1 has beenthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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bin [5]. Similar to thrombin, there is evidence suggesting that Factor
Xa is also involved in cellular activities, including inﬂammation, vascu-
lar remodeling, and tissue ﬁbrosis. Most of these activities of Factor Xa
are mediated via PAR-1 and PAR-2 [1,6].
Direct oral Factor Xa and thrombin inhibitors have been undergoing
extensive clinical evaluations for the prevention and treatment of
thromboembolic disorders but, to date, limited data are available on
their potential effects beyond anticoagulation [7–16]. Rivaroxaban, a
direct Factor Xa inhibitor, inhibits the activity of the prothrombinase
complex as well as free and clot-bound Factor Xa [17,18], thereby
suppressing thrombin generation. Based on the available evidence of
the involvement of thrombin and Factor Xa in other cellular activities,
such as inﬂammation, it is anticipated that inhibitors of these coagula-
tion proteases may have anti-inﬂammatory properties, in addition to
their well-established anticoagulant effect [19]. Vascular endothelial
cells play a central role in inﬂammation. They release cytokines and
are able to express adhesion molecules that promote inﬂammatory
responses [2].
The aim of this study was to assess the potential of the direct Factor
Xa inhibitor rivaroxaban to inhibit pro-inﬂammatory gene expression
in endothelial cells and to compare the effect with that of dabigatran
(a direct thrombin inhibitor). Therefore, we determined which genes
were most strongly affected by thrombin in endothelial cells and inves-
tigated to what extent the changes in gene expression were mediated
through PAR-1. The identiﬁed genes were then used to compare the
anti-inﬂammatory effects of rivaroxaban and dabigatran on plasma-
induced gene expression after stimulation of thrombin generation.
2. Materials and methods
Rivaroxaban, dabigatran etexilate, and vorapaxar (a PAR-1 receptor
antagonist) were synthesized at the chemical laboratories of Bayer
Pharma AG (Wuppertal, Germany). Dabigatran etexilate was dissolved
in 1MHCl as a stock solution (neutralized by bicarbonate in cell culture
buffer); rivaroxaban and vorapaxar were dissolved in dimethyl sulfox-
ide (DMSO; as 10 mM stock solutions) and diluted in endothelial cell
basal medium (EBM-2; Lonza, Basel, Switzerland) to the ﬁnal concen-
trations tested. The ﬁnal concentration of DMSO in cell cultures was
b0.03%.
2.1. Cell culture
Human umbilical vein endothelial cells (HUVECs) from pooled do-
nors (PromoCell, Heidelberg, Germany) were grown in EBM-2 supple-
mented with an endothelial cell BulletKit (EGM-2; Lonza) without
heparin. HUVECs, between passage 3 and 6, were cultured in uncoated
tissue culture dishes and maintained at 37°C in a humidiﬁed incubator
with 5% CO2. All HUVEC incubation experiments were carried out in
serum-free EBM-2 without any supplements but containing either
1 U mL−1 thrombin (Sigma-Aldrich, Munich, Germany) or human
citrated pooled plasma (Octapharma, Heidelberg, Germany) (3% v/v in
serum-free EBM-2) for speciﬁc time periods. Cell viability was tested
using ATP lite (Promega, Mannheim, Germany).
2.2. Microarray experiments
HUVECs were incubated with 1 U mL−1 thrombin in the absence or
presence of 1 μMvorapaxar for 4 h or the appropriate solvent. Total RNA
was isolated and microarray experiments were performed to identify
transcriptome-wide changes to mRNA expression levels induced by
thrombin.
Hybridization of Affymetrix GeneChip Human Gene 1.0 ST arrays
(Affymetrix, Santa Clara, CA, USA) was carried out as described previ-
ously [6]. In brief, 200 ng of total RNA from HUVECs was reverse-
transcribed into cDNA and ampliﬁed using T7 RNA polymerase. Thequality of the resulting cRNA was assessed using a 2100 Bioanalyzer
(Agilent Technologies,Waldbronn, Germany). Antisense RNAwas puri-
ﬁed and then used for another round of cDNA synthesis followed by
fragmentation and labeling of the cDNA before hybridization to
the microarrays. Each microarray was washed and stained with
streptavidin-phycoerythrin and then scanned using anAffymetrix Scan-
ner 3000 in accordance with manufacturer's instructions (Affymetrix).
Fluorescence intensities of scanned images were corrected for back-
ground noise and evaluated using Affymetrix Command Console®
Software (AGCC). Further statistical analysis was performed using ex-
pressionist software (GeneData, Basel, Switzerland).
2.3. Determination of pro-inﬂammatory gene expression by real-time PCR
Total RNA from HUVECs was isolated using an RNeasy kit (Qiagen,
Hilden, Germany) and checked for integrity on a Bioanalyzer (Agilent,
Heidelberg, Germany). For reverse-transcription, 1 μg of total RNA
was ﬁrst digested with RNase-free DNase I (Promega, Mannheim,
Germany) for 15 min at room temperature and reverse-transcribed
with the use of Promiscript-III (Promega) in a total reaction volume of
40 μl in accordance with the manufacturer's instructions. Real-time
PCRwas performed asdescribed previously [20]. Primerswere designed
using Primer Express Software (Applied Biosystems, Darmstadt,
Germany). Primer and probe sequences are given in Table A1. Cycle
threshold values were corrected for the housekeeping genes ribosomal
protein L32, β-2-microglobulin (B2M), and cytosolic β-actin (ACTB) to
exclude different starting amounts of total RNA. We observed that the
calculated expression level was independent of the housekeeping
gene used. Therefore, we decided to normalize all mRNA expression
data to ribosomal protein L32 using a modiﬁed ddCt-method, as
described previously [21]. The resulting expression levels are given in
arbitrary units that allow a direct comparison of themRNA levels across
the various genes examined in HUVECs. To evaluate the effect of
vorapaxar (0.1–10 nM), rivaroxaban (0.3–3000 nM), dabigatran
(0.3–10,000 nM), and the appropriate solvents on selected pro-
inﬂammatory gene expression levels, HUVECs were pretreated for
30 min with the respective inhibitors before plasma (3% v/v in serum-
free EBM-2) (as the source of thrombin), together with the same con-
centrations of the inhibitors as in the pretreatment step, was added to
the cells for an additional 4 h. EBM-2 medium served as the source of
Ca2+ to stimulate thrombin generation in the recalciﬁed plasma. Each
experimentwas run in duplicate and repeated in 4–20 different charges
of HUVECs (obtained from different donors to take into consideration
the physiologic variability of individual umbilical cords) depending on
the biomarker investigated and the inhibitor concentration used. The
expression level of each gene observed after incubation of HUVECs
with 3% citrated plasma was deﬁned as 100%.
2.4. Determination of thrombin activity
In HUVECs pretreated with rivaroxaban (0.3–10,000 nM),
dabigatran (0.3–10,000 nM), or the appropriate solvents, thrombin gen-
eration was induced by the addition of plasma (3% v/v in Ca2+-
containing serum-free EBM-2) as described above. After incubation at
37°C for 30 min, 60 min, and 120 min, respectively, the plasma was
withdrawn and centrifuged for 20 min at 1000 g. The supernatants
were stored at −20°C for 1 day. Thrombin activity was measured in
0.09pt?>microtiter plates via the cleavage of the ﬂuorogenic substrate
I-1560 (Bachem, Bubendorf, Switzerland), which was added at a ﬁnal
concentration of 50 μM to the supernatant. The hydrolysis of the
ﬂuorogenic substrate catalyzed by thrombin was monitored continu-
ously at 360/465 nm using a ﬂuorescence plate reader (Inﬁnite M1000
Pro, Tecan, Crailsheim, Germany) for 60 min at 37°C. The ﬂuorescent
signal is given as arbitrary units. Each experiment was repeated four
times using different charges of HUVECs. The ﬂuorogenic substrate
was reconstituted in DMSO.
Table 1
The 20most-strongly induced genes in human umbilical vein endothelial cells after treat-
ment with 1 U mL−1 thrombin (4 h).
Gene
symbol
Gene description Fold induction
by thrombin
SELE Selectin E (endothelial leukocyte adhesion
molecule 1) ELAM-1
88.40
VCAM-1 Vascular cell adhesion molecule 1 49.79
CCL20 Chemokine (C-C motif) ligand 20 (MIP-3A) 13.09
BIRC3 Baculoviral IAP repeat-containing 3 12.70
ICAM-1 Intercellular adhesion molecule 1 (CD54),
human rhinovirus
11.11
CD69 CD69 molecule 10.64
TRAF1 TNF receptor-associated factor 1 8.07
CCL2 Chemokine (C-C motif) ligand 2 (MCP-1) 7.50
IL-8 Interleukin 8 6.20
SLC7A2 Solute carrier family 7 5.72
SERPINB2 Serpin peptidase inhibitor, clade B (ovalbumin),
member 2
4.58
TNFAIP3 Tumor necrosis factor, alpha-induced protein 3 4.27
CXCL2 Chemokine (C-X-C motif) ligand 2 3.77
RND1 Rho family GTPase 1 3.69
SOD2 Superoxide dismutase 2, mitochondrial 3.36
TNFSF18 Tumor necrosis factor (ligand) superfamily,
member 18
3.30
TAGLN Transgelin 2.99
CXCL1 Chemokine (C-X-C motif) ligand 1 2.98
HBEGF Heparin-binding EGF-like growth factor 2.89
FBXO32 F-box protein 32 2.76
IL7R Interleukin 7 receptor 2.75
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Data are presented as mean values ± standard error of the mean.
Within-group differences were assessed by one-way analysis of vari-
ance (ANOVA) using GraphPad Prism 5.0 software followed by a post
hoc Dunnett's multiple comparison test. A value of P b 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. Transcriptional changes induced by thrombin
In total, 69 transcripts were identiﬁed for which expression levels
were altered more than twofold by thrombin (1 U mL−1) treatment
and had a microarray signal intensity of at least 40 relative ﬂuores-
cence intensity (RFI) units above background. As shown in Fig. 1,
the expression levels of only two of these 69 genes were not affected
by the PAR-1 antagonist vorapaxar, suggesting that virtually all
transcriptional effects of thrombin on HUVECs were exerted via
PAR-1-activation.
Thrombin induced the expression of adhesion molecules and in-
ﬂammatory cytokines. Among the genes inﬂuenced most were endo-
thelial leukocyte adhesion molecule 1 (ELAM-1; 88-fold), vascular cell
adhesion molecule 1 (VCAM-1; 50-fold), and intercellular adhesion
molecule 1 (ICAM-1; 11-fold) (Table 1). Chemokine (C-C motif) ligand
2 (MCP-1), interleukin (IL) 8 (IL-8), chemokine (C-X-C motif) ligand 1
(CXCL1), and chemokine (C-X-C motif) ligand 2 (CXCL2) were induced
by 7-, 6-, 3-, and 4-fold, respectively (Table 1). These genes and the gene
encoding TFwere selected for the subsequent experiments asmolecular
markers of pro-inﬂammatory thrombin activity on endothelial cells and
their expression levels were quantiﬁed by real-time PCR (see Table A1
for the sequences of PCR primers used).
3.2. Pro-inﬂammatory gene expression induced by recalciﬁed plasma
Recalciﬁed plasma as a potential source of thrombin for the incuba-
tion of HUVECs was compared directly with thrombin treatment. The
time course of pro-inﬂammatory gene expression induced by recalciﬁed
plasma or 1 U mL−1 thrombin is shown in Fig. 2. Gene expression
reached peak levels after a 4-h incubation period regardless of whether
recalciﬁed plasma or thrombin was used. Extending the incubation pe-
riod to 6 h did not lead to a stronger effect; rather, a slight decrease was
observed compared with the 4-h incubation period for most of the
genes examined (Fig. 2). Cell viability assays with HUVECs indicatedFig. 1. Effect of thrombin and thrombin plus the PAR-1 antagonist vorapaxar on transcriptional c
or presence of 1 μM of the PAR-1 antagonist vorapaxar. RNA was isolated and subjected to m
intensities are plotted on a log–log scale; blue lines indicate greater than twofold changes, r
untreated controls. Red crosses indicate transcripts with a greater than twofold change. HUVEthat slight cytotoxicity may have been responsible for this decrease in
signal after a 6-h incubation under serum-free conditions (viability
assay revealed N90% viable cells).
HUVECs were incubated in parallel with either an excess
of the thrombin inhibitor lepirudin (70 μg mL−1) or with 10 mM
Ca2+-chelating EGTA. The increased gene expression of adhesion mole-
cules and inﬂammatory cytokines in recalciﬁed plasma was completely
blocked by either lepirudin or EDTA (data not shown), suggesting that
the generated thrombin was the key mediator of the inﬂammatory
response.
Furthermore, vorapaxar signiﬁcantly inhibited expression of the
pro-inﬂammatory genes ELAM-1, ICAM-1, VCAM-1, IL-8, MCP-1,
CXCL1, CXCL2, and the gene encoding TF, in a concentration-
dependent manner. Nearly complete or complete inhibition was
achieved with 3–10 nM vorapaxar (Fig. A1), suggesting that the ef-
fects were mediated via PAR-1 activation.hanges inHUVECs. HUVECswere incubated for 4 hwith 1 UmL−1 thrombin in the absence
icroarray hybridization using the Affymetrix GeneChip Human Gene 1.0 ST array. Signal
ed lines greater than ﬁvefold changes, and green lines N10-fold changes compared with
C, human umbilical vein endothelial cell; PAR, proteinase-activated receptor.
Fig. 2. Time course of pro-inﬂammatory gene expression in HUVECs induced by
incubation with (A) 3% recalciﬁed plasma (3% v/v in serum-free endothelial cell basal
medium [EBM-2]) to stimulate thrombin generation or (B) 1 U mL−1 thrombin. RNA
was isolated and subjected to real-time PCR-based quantiﬁcation of gene expression
(TaqMan). Expression data were normalized to a housekeeping gene, and the
normalized expression level of each candidate gene before stimulation was set as 1.
Data are presented as the mean obtained from two individual experiments performed in
duplicate; for better visibility, the standard deviations were omitted. HUVEC, human
umbilical vein endothelial cell; TF, tissue factor.
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expression
The effects of rivaroxaban and dabigatran on ELAM-1, ICAM-1,
VCAM-1, IL-8, MCP-1, CXCL1, CXCL2, and TF induced by recalciﬁed
plasma are shown in Figs. 3 and 4. Rivaroxaban caused signiﬁcant,
concentration-dependent suppression of the expression of all
genes tested in the following rank order: VCAM-1 N ICAM-1 =
ELAM-1 N IL-8 = MCP-1 = CXCL1 = CXCL2 = TF, with maximal
suppression observed at 3000 nM (Fig. 3). Dabigatran also caused
signiﬁcant concentration-dependent inhibition of the expression
of all pro-inﬂammatory genes tested, achieving complete inhibi-
tion at 10,000 nM (Fig. 4). However, at concentrations below the
anti-inﬂammatory effective concentrations, dabigatran exhibited a pro-
inﬂammatory effect. Compared with the plasma control, treatment
with dabigatran signiﬁcantly increased the expression levels of TF,
CXCL2, IL-8, CXCL1, ELAM-1, and MCP-1 by 4.9-, 3.1-, 2.9-, 2.8-, 2.5-, and
1.8-fold, respectively, with a maximal effect observed at 10–30 nM de-
pending on the gene examined. The expression levels of ICAM-1 and
VCAM-1 were not signiﬁcantly increased by dabigatran.3.4. Effects of dabigatran and rivaroxaban on thrombin activity
To investigate whether the pro-inﬂammatory gene expression is
mediated by thrombin generated in the plasma (3% in medium) after
recalciﬁcation, its enzymatic activity was measured in the cell superna-
tants after an incubation time of up to 120min. In Fig. 5, the representa-
tive curves show the increase in the ﬂuorescence signal depending on
the concentration of rivaroxaban, dabigatran, or the appropriatesolvent. The hydrolysis rate of the ﬂuorogenic thrombin substrate was
concentration-dependently reduced in the presence of dabigatran as
well as rivaroxaban, indicating the generation of thrombin in the
recalciﬁed plasma. In rivaroxaban-treated plasma probes, complete re-
duction of thrombin activity was observed at increasing concentrations
of 0.3, 1.0, and 3.0 μMrivaroxaban after an incubation timeof 30, 60, and
120 min, respectively, demonstrating a continuous increase in throm-
bin. Similarly, dabigatran completely reduced thrombin activity at in-
creasing concentrations of 1.0, 1.0, and 3.0 μM after incubation times
of 30, 60, and 120 min, respectively. However, a biphasic response
with a transient increase in thrombin activity above control was ob-
served at 3–10 nM, 10–30 nM, and 30–100 nM dabigatran (concentra-
tions below minimal inhibitory effective concentrations) after 30, 60,
and 120 min, respectively.
4. Discussion
Thrombin is involved in a variety of physiologic and pathologic pro-
cesses, and the principal mechanism mediating these thrombin-
induced activities is PAR-1 receptor activation and signaling, although
it has been shown previously that transactivation of PAR-2 by
thrombin-cleaved PAR-1 can contribute to the thrombin response
[22]. Data from previous studies showed that most of the actions of
thrombin on endothelial cells could be produced using a PAR-1 agonist
peptide [4]. PAR-1 in endothelial cells contributes to angiogenesis, with
alterations to the expression levels of multiple genes, including cyto-
kines and cell adhesion molecules, as well as modulation of vascular
tone [4,23].
Data from this current study show that the transcriptional changes
exerted by thrombin on HUVECs are almost exclusively mediated via
PAR-1 activation. As shown in the microarray experiments, when the
HUVECs were incubated with thrombin in the presence of the selective
PAR-1 antagonist vorapaxar, the transcriptional changes induced by
thrombin were almost completely abolished (except for two of the 69
genes identiﬁed that were altered more than twofold by thrombin),
suggesting that transactivation of PAR-2 is negligible – at least under
the given experimental conditions. Among the genes that were most
strongly inﬂuenced by thrombin were ELAM-1, VCAM-1, ICAM-1,
MCP-1, IL-8, CXCL1, and CXCL2. These observations are consistent
with the existing data in the literature that thrombin promotes the ex-
pression of adhesionmolecules and cytokines in endothelial cells [4,23].
As part of the prothrombinase complex, Factor Xa catalyzes the con-
version of prothrombin to thrombin: one molecule of Factor Xa results
in the generation of approximately 1000 thrombin molecules [24,25].
Thus, by blocking thrombin generation, inhibition of Factor Xa may
also prevent cellular activities that thrombin exerts, such as inﬂamma-
tory reactions. To examine both Factor Xa and thrombin activity, we
studied the ability of recalciﬁed human plasma to stimulate gene ex-
pression in comparisonwith that induced by thrombin. The time course
and extent of pro-inﬂammatory gene expression were similar when
using plasma or thrombin, suggesting that the pro-inﬂammatory effect
of recalciﬁed plasma was indeed mediated by thrombin. Furthermore,
thrombin activity was veriﬁed in the recalciﬁed plasma. In addition,
the induction of gene expression in HUVECs on stimulation with
recalciﬁed plasma was completely inhibited by the thrombin inhibitor
lepirudin or by calcium-chelating EGTA (unpublished results). Finally,
vorapaxar concentration-dependently suppressed the expression
of pro-inﬂammatory genes in HUVECs, further supporting PAR-1-
mediated expression by thrombin and excluding any PAR-2-mediated
effect.
Direct inhibition of Factor Xa with rivaroxaban and thrombin inhibi-
tion with dabigatran completely downregulated recalciﬁed plasma-
induced expression of various pro-inﬂammatory markers. Because
rivaroxaban is a selective Factor Xa inhibitor without any direct effect
on thrombin activity, it can be concluded that the anti-inﬂammatory ef-
fects of rivaroxaban are attributed to its inhibition of thrombin
Fig. 3. Effect of rivaroxaban on plasma-induced pro-inﬂammatory gene expression after stimulation of thrombin generation in HUVECs. HUVECs were preincubated for 30 min with
rivaroxaban (0.3–3000 nM) before 3% recalciﬁed plasma (v/v in serum-free endothelial cell basal medium [EBM-2]) plus the same concentration of the inhibitor was added to the cells
for an additional 4 h. RNA was isolated and real-time PCR performed to quantify expression levels. Data are given as percent mRNA expression level compared with citrated plasma
only (deﬁned as 100%) and presented as mean ± standard error of the mean. *P b 0.05, **P b 0.01, ***P b 0.001. ELAM-1 (n = 4–15), ICAM-1 (n = 4–15), VCAM-1 (n = 3–15), IL-8
(n=4–15), MCP-1 (n=4–15), CXCL1 (n=3–15), CXCL2 (n=4–15), TF (n=4–15), and β-2-microglobulin (n=3–15). HUVEC, human umbilical vein endothelial cell; TF, tissue factor.
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signaling. This was supported by the data on thrombin activity, which
was concentration-dependently inhibited by rivaroxaban measured
after increasing incubation times. Similarly, dabigatran concentration-
dependently inhibited thrombin activity in the cell supernatant. The
concentrations needed to affect thrombin activity corresponded well
with the observed effects on pro-inﬂammatory gene expression.
The concentrations of rivaroxaban and dabigatran used in this study
were within the plasma concentration ranges after therapeutic doses of
these agents [26,27]; however, it should be emphasized that a direct
comparison of the doses/concentrations cannot be made owing to the
different conditions in in vitro studies and ex vivo plasma levels in
patients.
Previous studies have demonstrated an anti-inﬂammatory effect of
rivaroxaban. Our results are consistent with a recently reported study
in which rivaroxaban was shown to signiﬁcantly inhibit plasma-
induced upregulation of MCP-1 and ICAM-mRNA levels in HUVECs
[28]. The results of the present study also suggest that citrated plasma
could induce oxidative and inﬂammatory reactions in endothelial cells
via the activation of the thrombin–PAR-1 system. In another in vitro
study, rivaroxaban was shown to inhibit the secretion of inﬂammatorychemokines by activated monocytes and THP-1 cells, possibly via
blocking the generation of thrombin and thrombin-induced PAR-1 sig-
naling, in addition to inhibition of the procoagulant activity of activated
monocytes and macrophages. In clot-stimulated smooth muscle cells,
rivaroxaban reduced mRNA expression levels of the pro-inﬂammatory
mediators tumor necrosis factor (TNF)-α and IL-6 [15]. Furthermore,
in apolipoprotein E-deﬁcient mice with established atherosclerotic le-
sions, rivaroxaban reduced the expression of pro-inﬂammatory media-
tors in thoracic aortas, including IL-6, TNF-α, andMCP-1 [14]. In another
study in apolipoprotein E-deﬁcient mice, chronic administration of
rivaroxaban signiﬁcantly reduced atherosclerotic lesion progression in
the aortic arch, and this was accompanied by decreases in macrophage
accumulation in atherosclerotic plaques and the expression level of in-
ﬂammatory molecules (such as matrix metalloproteinase-9 [MMP-9]
and TNF-α) [10]. In a mouse model of type 2 diabetes mellitus,
rivaroxaban attenuated leukocyte adhesion and thrombus formation
in the microvasculature [29]. In a recent study of a rat model of brain
ischemia/perfusion injury, pretreatment with rivaroxaban was shown
to decrease stroke severity by a dual antithrombotic and anti-
inﬂammatory mechanism [9]. Clinical evidence came from a study
that examined plasma protein biomarkers in Japanese patients with
Fig. 4. Effect of dabigatran on plasma-induced pro-inﬂammatory gene expression after stimulation of thrombin generation in HUVECs. HUVECs were preincubated for 30 min with
dabigatran (0.3–10,000 nM) before 3% recalciﬁed plasma (v/v in serum-free endothelial cell basal medium [EBM-2]) plus the same concentration of the inhibitor was added to the
cells for an additional 4 h. RNA was isolated and real-time PCR performed to quantify expression levels. Data are given as percent mRNA expression level compared with citrated
plasma only (deﬁned as 100%) and presented as mean ± standard error of the mean. *P b 0.05, **P b 0.01, ***P b 0.001. ELAM-1 (n= 4–20), ICAM-1 (n= 4–20), VCAM-1 (n= 4–20),
IL-8 (n = 4–20), MCP-1 (n = 4–20), CXCL1 (n = 4–20), CXCL2 (n = 4–20), TF (n = 4–20), and β-2-microglobulin (n = 4–19). HUVEC, human umbilical vein endothelial cell; TF,
tissue factor.
49P. Ellinghaus et al. / Thrombosis Research 142 (2016) 44–51non-valvular chronic atrial ﬁbrillation. Compared with warfarin, treat-
ment with rivaroxaban for 24 weeks was associated with a signiﬁcant
increase in thrombomodulin (TM) level and a trend towards a reduction
inMMP-9 [8]. These studies, together with data from the present study,
provide evidence for an anti-inﬂammatory property of rivaroxaban, in
addition to its anticoagulant effect.
In the present study, low concentrations of dabigatran (3–300 nM)
signiﬁcantly increased the expression of most of the genes examined,
with the strongest effects seen for TF, followed by CXCL2, IL-8, CXCL1,
ELAM-1, and MCP-1; similarly, a biphasic response with a transient in-
crease in thrombin activity above controlwas observed at the same con-
centration range of dabigatran (3–100 nM) – concentrations that are
below the minimal inhibitory effective concentrations, after an incuba-
tion time of 30 min and up to 120 min. Such an effect was not observed
with rivaroxaban at any of the concentrations tested. Both dabigatran
and rivaroxaban had no effect on the negative control (B2M expres-
sion). Notably, the concentration–response curves varied between the
different studies owing to the different charges of HUVECs. The precise
reason for the pro-inﬂammatory effect observed with low concentra-
tions of dabigatran in the current study needs further investigations. Itwas shown previously that thrombin inhibitors (such as melagatran
and dabigatran) lead to increased thrombin generation in plasma
spikedwith TMat low concentrations, possibly via inhibition of the pro-
tein C (PC) system, resulting in lower activated protein C (APC) concen-
trations, in contrast to Factor Xa inhibitors such as rivaroxaban [30,31].
A more recent study investigated the effects of melagatran and
dabigatran on the negative-feedback system, activation of PC, and the
production and degradation of Factor Va in human plasma (as possible
mechanisms underlying the paradoxical enhancement of thrombin
generation). The results showed that melagatran and dabigatran
decreased plasma concentrations of APC–PC inhibitor complex at
≥25 nM and ≥75 nM, respectively, but that the direct Factor Xa inhib-
itor edoxaban required a much higher concentration to inhibit the
APC–PC inhibitor complex [32]. APC associated with endothelial PC
receptor exhibits cytoprotective signaling events through cleavage
of PAR-1 [33].
Further in vitro and animal studies to examine the protein levels of
these genes are needed to determine the biological relevance of the
ﬁndings for pro-inﬂammatory gene expression. An analysis of markers
of inﬂammation using blood samples from a phase II study of the oral
Fig. 5. Effect of rivaroxaban (A) and dabigatran (B) on thrombin activity after stimulation of thrombin generation in HUVECs. Thrombin generation was triggered by recalciﬁcation of the
plasma in the incubation medium (recalciﬁed plasma; 3% v/v in serum-free endothelial cell basal medium [EBM-2]) of HUVECs. Data presented are representative curves showing the
increase of the ﬂuorescence signal after hydrolysis of the ﬂuorogenic thrombin substrate over 60 min. HUVECs were preincubated for 30 min with rivaroxaban (0.3–10,000 nM) or
dabigatran (0.3–10,000 nM) before 3% recalciﬁed plasma with the same concentration of the inhibitor was added to the cells for 30, 60, and 120 min. Plasma was withdrawn and
thrombin activity was measured after the addition of the ﬂuorogenic thrombin substrate I-1560. Dabi, dabigatran; HUVEC, human umbilical vein endothelial cell; Riva, rivaroxaban.
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term treatment with ximelagatran in patients with myocardial infarc-
tion increased the levels of several markers of inﬂammation; the
authors speculated that inhibition of APC (by blocking thrombin activi-
ty) might be a contributing factor [34]. However, studies in an apolipo-
protein E-deﬁcient mouse model showed that dabigatran improved
endothelial function and reduced atherosclerotic lesions [12,13]. In ad-
dition, another study in this mouse model showed that dabigatran not
only reduced the lesion size but also increased the stability of the ath-
erosclerotic lesion and reduced the number of macrophages and the
aortic plaque content of MMP-9 [11].
It is well recognized that inﬂammation plays a key role in the path-
ogenesis of cardiovascular diseases [2,35]. Thus, in addition to its anti-
thrombotic effects, direct Factor Xa inhibition with rivaroxaban, as
well as direct thrombin inhibition with dabigatran, might haveadditional, anti-inﬂammatory beneﬁts. However, data from preclinical
studies may not always translate into patients in a clinical setting;
therefore, the relevance of these preclinical ﬁndings remains to be
established.
In summary, data from this study further conﬁrm that thrombin-
induced transcriptional changes are mediated by PAR-1. Rivaroxaban
concentration-dependently suppressed the expression of various pro-
inﬂammatory markers to a similar extent to dabigatran. However, in
contrast to rivaroxaban, dabigatran exhibited a biphasic response with
a transient increase in the expression of most of the genes examined
at concentrations below the minimal inhibitory effective concentra-
tions. Future studies investigating the inﬂuence of these direct oral anti-
coagulants on the thrombin/APC/TM/endothelial PC receptor system,
and the levels of inﬂammatory markers in patients receiving long-
term rivaroxaban or dabigatran treatment, would offer further insight.
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